Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The footer’s site revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 error.
    Difference
    0.3%
    Check dated 2026-11-01T15:49:24.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    A dismissible NIH banner announces website updates and a transition from “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    1%
    Check dated 2026-10-25T15:37:30.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page displays an updated site revision identifier, from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T22:20:57.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T21:57:33.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    A 403 Forbidden page appears, replacing the study details and related sections with an error screen, making the record inaccessible to users.
    Difference
    19%
    Check dated 2026-09-20T19:51:47.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.5 to v3.6.6. This indicates a new build/version of the page.
    Difference
    0.1%
    Check dated 2026-08-30T21:41:13.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.